+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pneumonia Therapeutics Market - Global Forecast 2026-2032- Product Image
Pneumonia Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Pneumonia Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888889
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pneumonia Therapeutics Market is projected to reach USD 4.04 Billion in 2026. It is expected to continue growing at a CAGR of 8.89%, reaching USD 6.74 Billion by 2032.

Pneumonia therapeutics encompasses medicines and supportive interventions used to manage bacterial, viral, fungal, and aspiration-related pneumonia across community and healthcare settings. Treatment decisions depend on pathogen risk, disease severity, age, comorbidities, local resistance patterns, vaccination status, and care setting. The field is shifting toward faster diagnosis, more targeted antimicrobial use, improved supportive care, and stronger prevention strategies.

Treatment Is Shifting Toward Precision, Stewardship, and Prevention

The therapeutic landscape is being reshaped by antimicrobial resistance, greater attention to viral causes, and demand for rapid differentiation between bacterial and non-bacterial illness. Hospitals and public-health systems are strengthening stewardship programs, diagnostic pathways, infection-control practices, and vaccination delivery. Oral-to-intravenous treatment transitions, shorter evidence-based regimens where appropriate, and standardized severity assessment are also supporting more efficient care while preserving treatment safety.

Artificial Intelligence Strengthens Diagnosis and Clinical Decision Support

Artificial intelligence is increasingly applied to chest-image interpretation, clinical deterioration alerts, pathogen identification, and antimicrobial decision support. Its practical value depends on representative training data, prospective validation, clinician oversight, interoperability, and transparent performance monitoring. AI can help prioritize high-risk patients and reduce diagnostic delays, but it does not replace microbiological testing, clinical judgment, or stewardship governance.

Regional Insights: Uneven Burden and Health-System Readiness

North America and Europe generally benefit from established diagnostic, hospital, vaccination, and stewardship infrastructure, while continuing to address resistant pathogens, aging populations, and care disparities. Asia-Pacific combines substantial variation in access, urbanization, respiratory-disease burden, and manufacturing capacity, creating a strong need for scalable diagnostics and appropriate antimicrobial use. Latin America faces uneven access and resistance surveillance, with opportunities to expand primary care and vaccination. The Middle East is influenced by specialized hospital capacity, population mobility, and chronic-disease prevalence. Africa requires stronger laboratory networks, oxygen and inpatient capacity, reliable medicine access, and integrated prevention programs.

Group Insights: Cooperation Shapes Access and Stewardship

ASEAN priorities include cross-border surveillance, affordable diagnostics, and consistent treatment guidance across diverse health systems. BRICS members can support collaboration on local manufacturing, research, resistance monitoring, and access to essential therapies. The European Union benefits from coordinated regulatory and surveillance mechanisms, while the G7 can advance financing, innovation, and global preparedness. GCC health systems can emphasize hospital quality, vaccination, and regional procurement. NATO members have a shared interest in resilient medical supply chains, outbreak readiness, and continuity of care during emergencies.

Country Insights: Diverse Priorities Across Major Health Systems

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States are focused on stewardship, aging-related vulnerability, diagnostics, vaccination, and hospital-care quality, with national differences in reimbursement and guidelines. Brazil, China, India, Mexico, and Russia face varied combinations of access constraints, regional inequality, antimicrobial resistance, and diagnostic capacity. Across these countries, priorities include dependable supply, locally relevant surveillance, appropriate use of antibiotics, improved respiratory support, and faster identification of severe disease.

Actions for Leaders: Build Resilient, Evidence-Based Care Pathways

Industry leaders should align product development with clearly defined clinical gaps, including resistant infections, severe disease, pediatric and older-adult care, and settings with limited diagnostics. Evidence generation should include real-world outcomes, stewardship impact, safety in vulnerable populations, and performance across diverse geographies. Organizations should invest in diagnostic partnerships, responsible AI validation, supply-chain redundancy, clinician education, and equitable access models. Collaboration with hospitals, public-health agencies, laboratories, and community providers can improve adoption while supporting appropriate use.

Methodology: Evidence-Led Executive Synthesis

This executive summary uses the specified pneumonia therapeutics scope and synthesizes established clinical, public-health, and health-system themes without presenting market estimates, shares, sizing, or forecasts. Insights are organized across treatment evolution, artificial intelligence, regions, country groupings, and individual countries. Interpretation emphasizes clinically relevant drivers, access conditions, stewardship, diagnostics, prevention, and operational readiness; claims should be validated against current national guidelines, surveillance data, and peer-reviewed evidence before use in decision-making.

Conclusion: Integrate Treatment, Diagnostics, Prevention, and Access

Pneumonia therapeutics is progressing from treatment centered primarily on medication selection toward integrated pathways combining rapid diagnosis, antimicrobial stewardship, supportive care, vaccination, and resilient delivery systems. Regional and national differences make adaptable implementation essential. Leaders that connect clinical evidence with surveillance, responsible digital tools, reliable supply, and equitable access will be better positioned to improve outcomes while limiting avoidable antimicrobial exposure.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Pneumonia Therapeutics Market, by Product
7.1. Introduction
7.2. Drugs
7.2.1. Antibiotics
7.2.2. Antivirals
7.2.3. Antifungals
7.3. Vaccines
7.3.1. Pneumococcal vaccines
7.3.2. Influenza vaccines
8. Pneumonia Therapeutics Market, by Mode of Infection
8.1. Introduction
8.2. Community-acquired pneumonia (CAP)
8.3. Hospital-acquired pneumonia (HAP)
8.4. Ventilator-associated pneumonia (VAP)
8.5. Aspiration pneumonia
9. Pneumonia Therapeutics Market, by Route of Administration
9.1. Introduction
9.2. Oral
9.3. Intravenous (IV)
9.4. Intramuscular (IM)
9.5. Inhalation
10. Pneumonia Therapeutics Market, by Age Group
10.1. Introduction
10.2. Pediatric
10.3. Adults
10.4. Geriatric
11. Pneumonia Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Online
11.3. Offline
12. Pneumonia Therapeutics Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. Europe
12.4. North America
12.5. Latin America
12.6. Africa
12.7. Middle East
13. Pneumonia Therapeutics Market, by Group
13.1. Introduction
13.2. NATO
13.3. G7
13.4. BRICS
13.5. European Union
13.6. ASEAN
13.7. GCC
14. Pneumonia Therapeutics Market, by Country
14.1. Introduction
14.2. China
14.3. United States
14.4. Japan
14.5. India
14.6. Germany
14.7. United Kingdom
14.8. Australia
14.9. France
14.10. South Korea
14.11. Italy
14.12. Canada
14.13. Russia
14.14. Brazil
14.15. Mexico
14.16. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. AstraZeneca PLC
16.3. Aurobindo Pharma Limited
16.4. Bayer AG
16.5. Biobrick Pharma Private Limited
16.6. Cipla Limited
16.7. Dr. Reddy's Laboratories Limited
16.8. Eli Lilly and Company
16.9. F. Hoffmann-La Roche Ltd.
16.10. GSK plc
16.11. Hikma Pharmaceuticals PLC
16.12. Lincoln Pharmaceuticals Limited
16.13. Mankind Pharma Limited
16.14. Merck & Co., Inc.
16.15. Novartis AG
16.16. Pfizer Inc.
16.17. Sanofi
16.18. Serum Institute of India Private Limited
16.19. Sun Pharmaceutical Industries Limited
16.20. Teva Pharmaceutical Industries Ltd.
16.21. Viatris Inc.
16.22. Wellona Pharma Private Limited
17. Key Experts
List of Figures
FIGURE 1. Global Pneumonia Therapeutics Market, Years Considered for the Study
FIGURE 2. Global Pneumonia Therapeutics Market, Research Design
FIGURE 3. Global Pneumonia Therapeutics Market, Research Framework
FIGURE 4. Global Pneumonia Therapeutics Market, Data Triangulation
FIGURE 5. Global Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Pneumonia Therapeutics Market Size, by Product, 2025 vs 2032 (%)
FIGURE 7. Global Pneumonia Therapeutics Market Size, by Product, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Pneumonia Therapeutics Market Size, by Mode of Infection, 2025 vs 2032 (%)
FIGURE 9. Global Pneumonia Therapeutics Market Size, by Mode of Infection, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Pneumonia Therapeutics Market Size, by Route of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Pneumonia Therapeutics Market Size, by Route of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Pneumonia Therapeutics Market Size, by Age Group, 2025 vs 2032 (%)
FIGURE 13. Global Pneumonia Therapeutics Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Pneumonia Therapeutics Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Pneumonia Therapeutics Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Pneumonia Therapeutics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Pneumonia Therapeutics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Pneumonia Therapeutics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Pneumonia Therapeutics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Pneumonia Therapeutics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Pneumonia Therapeutics Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Pneumonia Therapeutics Market Segmentation & Coverage
TABLE 2. Global Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 3. Global Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 4. Global Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Antibiotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Antibiotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Antibiotics Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Antivirals Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Antivirals Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Antivirals Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Antifungals Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Antifungals Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Antifungals Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Pneumococcal vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Pneumococcal vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Pneumococcal vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Influenza vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Influenza vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Influenza vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 26. Global Community-acquired pneumonia (CAP) Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Community-acquired pneumonia (CAP) Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Community-acquired pneumonia (CAP) Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Hospital-acquired pneumonia (HAP) Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Hospital-acquired pneumonia (HAP) Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Hospital-acquired pneumonia (HAP) Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Ventilator-associated pneumonia (VAP) Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Ventilator-associated pneumonia (VAP) Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Ventilator-associated pneumonia (VAP) Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Aspiration pneumonia Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Aspiration pneumonia Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Aspiration pneumonia Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 39. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Intravenous (IV) Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Intravenous (IV) Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Intravenous (IV) Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Intramuscular (IM) Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Intramuscular (IM) Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Intramuscular (IM) Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Inhalation Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Inhalation Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Inhalation Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 52. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Adults Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Adults Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Adults Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 62. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Pneumonia Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Pneumonia Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. Europe Pneumonia Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Europe Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 79. Europe Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 80. Europe Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 81. Europe Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 82. Europe Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 83. Europe Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 84. Europe Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 85. North America Pneumonia Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. North America Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 87. North America Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 88. North America Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 89. North America Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 90. North America Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 91. North America Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 92. North America Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. Latin America Pneumonia Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Latin America Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 95. Latin America Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 96. Latin America Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 97. Latin America Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 98. Latin America Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 99. Latin America Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 100. Latin America Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 101. Africa Pneumonia Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Africa Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 103. Africa Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 104. Africa Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 105. Africa Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 106. Africa Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 107. Africa Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 108. Africa Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 109. Middle East Pneumonia Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Middle East Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 111. Middle East Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 112. Middle East Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 113. Middle East Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 114. Middle East Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 115. Middle East Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 116. Middle East Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. Global Pneumonia Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. NATO Pneumonia Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. NATO Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 120. NATO Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 121. NATO Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 122. NATO Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 123. NATO Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 124. NATO Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 125. NATO Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. G7 Pneumonia Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. G7 Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 128. G7 Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 129. G7 Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 130. G7 Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 131. G7 Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 132. G7 Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 133. G7 Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. BRICS Pneumonia Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. BRICS Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 136. BRICS Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 137. BRICS Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 138. BRICS Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 139. BRICS Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 140. BRICS Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 141. BRICS Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 142. European Union Pneumonia Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. European Union Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 144. European Union Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 145. European Union Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 146. European Union Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 147. European Union Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 148. European Union Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 149. European Union Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 150. ASEAN Pneumonia Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. ASEAN Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 152. ASEAN Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 153. ASEAN Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 154. ASEAN Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 155. ASEAN Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 156. ASEAN Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 157. ASEAN Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 158. GCC Pneumonia Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 159. GCC Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 160. GCC Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 161. GCC Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 162. GCC Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 163. GCC Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 164. GCC Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 165. GCC Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. Global Pneumonia Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 167. China Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 168. China Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 169. China Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 170. China Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 171. China Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 172. China Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 173. China Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 174. China Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. United States Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 176. United States Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 177. United States Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 178. United States Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 179. United States Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 180. United States Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 181. United States Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 182. United States Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 183. Japan Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 184. Japan Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 185. Japan Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 186. Japan Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 187. Japan Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 188. Japan Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 189. Japan Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 190. Japan Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. India Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 192. India Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 193. India Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 194. India Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 195. India Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 196. India Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 197. India Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 198. India Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 199. Germany Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 200. Germany Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 201. Germany Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 202. Germany Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 203. Germany Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 204. Germany Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 205. Germany Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 206. Germany Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 207. United Kingdom Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 208. United Kingdom Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 209. United Kingdom Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 210. United Kingdom Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 211. United Kingdom Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 212. United Kingdom Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 213. United Kingdom Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 214. United Kingdom Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 215. Australia Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 216. Australia Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 217. Australia Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 218. Australia Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 219. Australia Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 220. Australia Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 221. Australia Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 222. Australia Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. France Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 224. France Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 225. France Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 226. France Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 227. France Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 228. France Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 229. France Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 230. France Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 231. South Korea Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 232. South Korea Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 233. South Korea Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 234. South Korea Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 235. South Korea Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 236. South Korea Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 237. South Korea Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 238. South Korea Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. Italy Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 240. Italy Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 241. Italy Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 242. Italy Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 243. Italy Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 244. Italy Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 245. Italy Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 246. Italy Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 247. Canada Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 248. Canada Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 249. Canada Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 250. Canada Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 251. Canada Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 252. Canada Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 253. Canada Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 254. Canada Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 255. Russia Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 256. Russia Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 257. Russia Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 258. Russia Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 259. Russia Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 260. Russia Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 261. Russia Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 262. Russia Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 263. Brazil Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 264. Brazil Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 265. Brazil Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 266. Brazil Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 267. Brazil Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 268. Brazil Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 269. Brazil Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 270. Brazil Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 271. Mexico Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 272. Mexico Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 273. Mexico Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 274. Mexico Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 275. Mexico Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 276. Mexico Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 277. Mexico Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 278. Mexico Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 279. Spain Pneumonia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 280. Spain Pneumonia Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 281. Spain Pneumonia Therapeutics Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 282. Spain Pneumonia Therapeutics Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 283. Spain Pneumonia Therapeutics Market Size, by Mode of Infection, 2017-2032 (USD Million)
TABLE 284. Spain Pneumonia Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 285. Spain Pneumonia Therapeutics Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 286. Spain Pneumonia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 287. Global Pneumonia Therapeutics Market Share, by Key Player, 2025
TABLE 288. Global Pneumonia Therapeutics Market, Key Experts

Companies Mentioned

  • Abbott Laboratories
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biobrick Pharma Private Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • Hikma Pharmaceuticals PLC
  • Lincoln Pharmaceuticals Limited
  • Mankind Pharma Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Private Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Wellona Pharma Private Limited

Table Information

Report AttributeDetails
No. of Pages180
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.04 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.74 Billion
Compound Annual Growth Rate8.8%
Regions CoveredGlobal
No. of Companies Mentioned22

Related Topics

Related Reports

Respiratory Tract Infection Therapeutic Market - Global Forecast 2026-2032 - Product Image

Respiratory Tract Infection Therapeutic Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Pneumonia Therapeutics - Global Strategic Business Report - Product Image

Pneumonia Therapeutics - Global Strategic Business Report

  • Report
  • 247 Pages
  • Global
From
Pneumonia Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025-2033 - Product Image

Pneumonia Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025-2033

  • Report
  • 181 Pages
  • Global
From
Linezolid for Oral Suspension Market - Global Forecast 2026-2032 - Product Image

Linezolid for Oral Suspension Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Pneumonia Therapeutics Market Report 2026 - Product Image

Pneumonia Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Pneumonia Drug Market

The Pneumonia Drug market is a subset of the larger Respiratory Drugs market. It includes drugs used to treat bacterial, viral, and fungal pneumonia, as well as other respiratory infections. These drugs are typically administered orally, intravenously, or intramuscularly, depending on the severity of the infection. Commonly prescribed drugs include antibiotics, antivirals, antifungals, and corticosteroids. In addition, some drugs are used to reduce inflammation and improve breathing. The Pneumonia Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck, Sanofi, AstraZeneca, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.